Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ATL 1102

Drug Profile

ATL 1102

Alternative Names: ATL-1102; ATL/TV-1102; ISIS-107248; TV-1102

Latest Information Update: 29 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Isis Pharmaceuticals
  • Developer Antisense Therapeutics; Childrens Hospital Los Angeles
  • Class Anti-inflammatories; Antineoplastics; Antirheumatics; Antisense oligonucleotides
  • Mechanism of Action Integrin alpha4 inhibitors; Integrin alpha4beta1 antagonists; RNA inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Asthma; Multiple sclerosis

Highest Development Phases

  • Phase II Duchenne muscular dystrophy; Multiple sclerosis
  • Preclinical Cancer
  • No development reported Asthma
  • Discontinued Stem cell mobilisation; Vertigo

Most Recent Events

  • 18 Nov 2019 Efficacy data from phase II trials in Duchenne muscular dystrophy released by Antisense Therapeutics
  • 17 Sep 2019 Antisense Therapeutics plans three Scientific Advice meetings with European regulatory authorities to review the planned phase IIb trial in Duchenne muscular dystrophy
  • 17 Sep 2019 Antisense Therapeutics plans a Scientific Advice meeting with European regulatory authorities to review the planned phase IIb trial in Duchenne muscular dystrophy, in October 2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top